More than a decade ago, the anticoagulant apixaban, trade name Eliquis, was shown to be superior to aspirin for preventing recurrent stroke in patients with a heart condition called atrial fibrillation. But a multi-center, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to results reported by researchers at Weill Cornell Medicine, Columbia...
Read More